Sun Pharmaceutical Secured Global Licensing for Lerodalcibep
The company entered a strategic partnership with LIB Therapeutics to expand access to a PCSK9 inhibitor.
Updated on Sept. 28, 2026 in Healthcare
Live Poll
Do you trust pharmaceutical companies to prioritize patient accessibility when bringing new treatments to global markets?
Sun Pharmaceutical Industries has entered a global licensing, commercialization, and manufacturing agreement with LIB Therapeutics. The partnership focuses on the cholesterol drug lerodalcibep, an antibody-mimetic biologic that inhibits PCSK9.
Why it matters
The collaboration aims to address critical unmet needs in cardiovascular care by providing additional LDL-C reduction options for high-risk patients. These patients often require treatment beyond standard statin therapy to reach their clinical goals.
The global PCSK9 inhibitor market reached $3.7 billion in the period ending Q2 2026, with Europe accounting for $2.9 billion of that total. Sun Pharma shares closed at ₹1,855.9 before the announcement.
The players
Sun Pharmaceutical Industries
This is a multinational pharmaceutical company that specializes in the production of generic and specialty medicines.
LIB Therapeutics
This is a biopharmaceutical company focused on developing therapies for cardiovascular diseases.
The details
Lerodalcibep is approved as Lyrokaul in the European Union for treating hypercholesterolaemia and mixed dyslipidaemia, and as Lerochol in the U.S. for reducing LDL-C in adults. The drug is administered as a monthly 300 mg subcutaneous injection and is formulated for six-month ambient storage.
Timeline
The PCSK9 inhibitor market reached $3.7 billion in Q2 2026.
Sun Pharma announced the licensing agreement on September 28, 2026.
Market Landscape
This deal underscores the intensifying competition within the PCSK9 inhibitor class, a critical segment for managing high cardiovascular risk. By securing these rights, Sun Pharma is positioning itself to capture market share against established cardiovascular therapies.
Patients currently utilizing or seeking PCSK9 inhibitors may see improved availability of this treatment in various international markets. The transition to a six-month ambient storage formulation potentially simplifies logistics for pharmacies and healthcare providers.
The takeaway
This partnership highlights the continued industry focus on improving cholesterol management for patients who do not respond to traditional statins. The move points to a broader trend where major pharmaceutical firms seek to expand access to injectable biologics in global markets.
Further reading
Learn more about the latest innovations in the Healthcare sector.
Live Poll
Do you trust pharmaceutical companies to prioritize patient accessibility when bringing new treatments to global markets?
